Navigation Links
New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
Date:9/6/2007

s of STAT4 have a 60 percent increased risk, Dr. Gregersen said. Rheumatoid arthritis is a painful inflammatory condition of the joints. It is an autoimmune disease, which means the body's immune system recognizes a product in the lining of the joint as foreign and wages an attack. Patients with lupus, also an autoimmune disease, have about double the risk compared to people without this variant of STAT4.

In a companion study by Dr. Gregersen and his colleagues, STAT4 popped up as an important risk gene in a population of patients in Korea. This paper is published this month in Molecular Medicine.

One percent of people will develop rheumatoid arthritis. There are probably dozens of genes, perhaps more, involved in triggering complex diseases like rheumatoid arthritis.

"Identifying this risk gene is important because it points us in the right direction," said Dr. Gregersen, who also just completed a whole genome-wide association study of rheumatoid arthritis that will appear later this month in the NEJM. The study is online as of September 6th with an accompanying editorial. In this paper, the scientists identified another risk gene -- TRAF1-C5.

"The identification of these two new autoimmunity genes has profound significance for our understanding of these complex diseases and our ability to develop more specific diagnostic tests and therapies," said Lindsey Criswell, MD, PhD, professor of medicine at UCSF and a co-investigator on both studies.

A lot is known about the STAT4 gene and the protein it makes. STAT4 is a signaling molecule that mediates the effects of immune system cytokines such as IL12 and some types of interferon. STAT4 controls the differentiation of T- cells into TH1 cells and may contribute to the development of TH17 cells, both of which seem to have a role in maintaining chronic inflammation in the body.

Inhibiting STAT4 can prevent or ameliorate arthritis in animal models of rheumatoid arthritis, suggesting that
'/>"/>

SOURCE The Feinstein Institute for Medical Research
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
2. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
3. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
4. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
5. Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study
6. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
7. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
8. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
9. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
10. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... evolving set of regulations, Ethics & Compliance professionals ... according to a new survey issued today by ... services and education. An overwhelming majority of respondents ... far the most important component of E&C training ...
(Date:3/5/2015)... --  ndd Medical Technologies , a leader in innovative ... technology, announced that its EasyOne Pro® was used at ... Pulmonary Fibrosis Support Group. The clinic targeted patients with ... well as those suspected of having ILD or PF. ... square inches, EasyOne Pro provides accurate respiratory test results ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... and Phase 1b Combination Clinical Trials ... Anti-Leukemic Activity, SOUTH SAN FRANCISCO, Calif., June 16 ... two,clinical trials of the company,s lead drug candidate, voreloxin (formerly,SNS-595), ... when,used as a single agent in relapsed or refractory patients ...
... Patients Not Optimally Controlled with, Levodopa ... Hours Per Day, RESEARCH TRIANGLE PARK, N.C., ... announced the approval of Requip(R),XL(TM) (ropinirole extended-release tablets) ... and symptoms of idiopathic Parkinson,s disease. Requip XL ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 ... publishing company, created a unique ‘energy’ experiment to ... lives. , After quick ‘5 -7 ... more than 150+ countries reported their life improving ... respondents reported positive results. , According to research, ...
(Date:3/6/2015)... 2015 Dr. Mark Sowell recently returned from ... AZ. Offering programs for advanced education in the field of ... , As a visiting faculty member of this prestigious ... each time he visits Spear Education to participate in a ... “we are training only the top 10% and those willing ...
(Date:3/6/2015)... Alexandria, Virginia (PRWEB) March 06, 2015 ... today it has awarded five-year accreditation status to seven ... Committee mean that another 1.3 million people can now ... to protect and promote the health of their communities. ... protecting and improving the health of people and communities. ...
(Date:3/5/2015)... March 05, 2015 Shania Twain will ... than a decade. She has hinted that this will be ... seeing her perform one last time. She has had a ... beloved country sweetheart has millions of loyal fans around the world. ... native country, Canada, and on June 30th she will be at ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Risperdal ... in a Pennsylvania mass tort litigation currently underway ... a jury has begun hearing testimony in the ... atypical antipsychotic medication can cause gynecomastia, or male ... in question was filed on behalf of a ...
Breaking Medicine News(10 mins):Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... journal Addiction , researchers from Bowling Green State ... and substantially elevated risks for illegal drug use in ... incarcerated in the United States has sharply risen over ... to 2,250,000 in 2006. So too has the number ...
... 28, 2010 (Geneva, Switzerland) At the UN Millennium ... world leaders gathered to review progress on the eight ... ill-health by 2015. As the summit came to a ... $40bn to reach the goals, with particular emphasis on ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Sept. ... C-reactive protein (CRP) can vary among different racial and ... heart-disease risk and the value of cholesterol-lowering drugs, a ... of inflammation, and elevated levels have been linked -- ...
... , TUESDAY, Sept. 28 (HealthDay News) -- Think recess, and ... in the school day set aside for running and playing, ... life. What if your workplace started offering recess on the ... good idea but possibly one of the most solid tactics ...
... treatments for the disease or enable earlier diagnosis, say the ... Dentistry. Pancreatic cancer has the lowest survival rate of all ... stages, late diagnosis and its resistance to chemotherapy and radiation ... Research Fund found that nearly three quarters of pancreatic ...
... your ragweed allergies, according to a study from Queen,s University. ... develop ragweed allergy symptoms more quickly than others. But the ... swing, those symptom differences subside. The team, led ... medicine and microbiology & immunology, exposed 123 participants to ragweed, ...
Cached Medicine News:Health News:Father's incarceration associated with elevated risks of marijuana and other illegal drug use 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 3Health News:C-Reactive Protein Levels Vary By Race: Study 2Health News:C-Reactive Protein Levels Vary By Race: Study 3Health News:Adding Recess to the Workday Gains Backers 2Health News:Adding Recess to the Workday Gains Backers 3Health News:Adding Recess to the Workday Gains Backers 4Health News:Protein key to growth of pancreatic cancer 2
... Technologies, The UroMax Ultra ia designed ... high pressure and low profile., Refolding ... a remarkably strong material that is ... materials., Non-Compliant Balloons, A compliant balloon ...
... Fr Diameter with Two Large Working Channels; ... MICRO-6 Semi-Rigid Ureteroscope is the smallest ureteroscope ... and therapeutic procedures. The ACMI MICRO-6 Ureteroscope ... procedures with minimal or no dilation or ...
... is a self-dilating, semi-rigid autoclavable operating ureteroscope ... image bundle for an enhanced, clear image. ... to "0" diopters. The direction of view ... passage. The straight access operating channel is ...
... tip diameter of only 6.9Fr (2.3mm) ... range of 180 for and easy ... observation, a new optical system has ... (3.9mm) sheath dilator, 0.035" guidewire compatible, ...
Medicine Products: